Hovione to Expand its New Jersey Facility
News Oct 03, 2015
Hovione is expanding its New Jersey facility in East Windsor, US to meet the increasing demands of its customers and to give them more options for spray drying manufacturing.
The expansion will add 30,600ft2 (2,843m2) to the 24,000ft2 (2,211m2) facility. It will include a new commercial spray dryer unit to complement the firm's existing pilot unit and this installation will be specifically designed to handle potent drug substances (APIs).
Drug substance capacity will also more than double at the site to support the needs of current and potential new customers.
Hovione said around 60 new jobs will be added to the current workforce at the plant.
'Expanding our manufacturing presence in the US highlights our commitment to our customers that want to manufacture their products in the US and to support the development needs of our ever expanding local customer base.
'The additional capacity will give us more flexibility and make us more agile to deal with our customer’s fast-paced projects,' said Dr Marco Gil, General Manager, Hovione New Jersey.
Dave Hoffman, President of Hovione's US Operations, said: 'This investment pays a tribute to the excellent work that the Hovione New Jersey team has done to create a sustainable business for the company in the US. We trust the team in New Jersey to be an integral part of Hovione’s overall expansion.'
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018